MAP2K7 and melanoma: In patients with advanced BRAFV600 mutant melanoma, the combination of a BRAF inhibitor, which blocks mutant BRAFV600, and an MEK inhibitor, which blocks the downstream protein MEK, has shown impressive activity, with objective response rates ranging from 64 to 70% [3,4,5].